Ask the expert: Are online innovations the future of Parkinson’s treatment?
Author: Sophie BatesPublished: 14 May 2020
Prep: Cook: Serves:
In the latest in our Ask the Expert series, we speak with neurologist Joaquim Ferreira, about the importance of online resources for people with Parkinson’s during the Covid-19 pandemic and how the crisis has led to new forms of clinical communication
Could you tell us how online therapies for people with Parkinson’s are evolving?
Parkinson’s is complex in its clinical presentation – symptoms vary and the condition is not easy to understand, even by healthcare professionals. We are learning that simple aspects regarding the way the diagnosis is made and communicated have prognostic implications, so educating the Parkinson’s community is extremely important.
New healthcare concepts of multidisciplinary and home or community-based interventions are being evaluated in an attempt to define the best way of combining different therapeutic interventions. These new healthcare models include education components and should be addressed in the same way as other health conditions. Likewise, the use of web-based interventions appears as an efficient way to target and hopefully benefit many people with Parkinson’s.
Why is accessing online information about Parkinson’s particularly important during the Covid-19 crisis?
Parkinson’s is a condition that needs continuous follow-up and management, so it’s critical to maintain care and monitoring even when we cannot access clinics in the same way. Keeping up therapeutic programmes is very important to avoid losing the benefits. We have been learning that non-pharmacological treatments – for instance, physiotherapy and speech therapy, have a duration of effect like any drug, so once they are stopped, the effects start to disappear. In the same way that we should not stop taking anti-parkinsonian medication (like drugs that release dopamine or mimic the action of dopamine) without professional advice, therapeutic treatments shouldn’t be stopped.
What role can other online resources play for people with Parkinson’s during the crisis?
The available resources are not enough for the mission we have. Not everything during the pandemic has been negative – this period has forced us to discover new ways that we can be involved in the care of individuals. The use of online tools has allowed us to perform consultations and therapeutic sessions – and we have been able to conclude surprisingly quickly that these tools work.
In terms of the future, online resources will allow a better documentation of what happens in the daily routines of people with Parkinson’s. Physicians will be able to access the real data of individuals from the information collected during face-to-face consultations, which will mean a ‘closer’ follow up – merging outpatient consultations with online interventions and support. So, in my opinion, online visits and sessions are here to stay.
You are the founder of neurological disorders centre Campus Neurológico Sénior (CNS). Could you tell us about the CNS Academy videos and how they benefit people with Parkinson’s?
The main purpose of CNS is to reunite quality clinical activity, leading research projects and training health professionals. The CNS Academy videos present the great work being done by our professionals and highlight our perception that there’s still a huge need for simple and high-quality information for everyone with Parkinson’s. We created these videos because we felt compelled to share the expertise of our dedicated and highly trained professionals – so that others can benefit from their knowledge.
The topics – which were suggested by healthcare professionals working at CNS – try to cover the most frequent and relevant problems that can be addressed by cartoons. They include educational videos on how to manage medication, home safety, how to help the caregiver, speech problems, gait problems etc. The videos’ objective is not just to propose simple tips, but to promote the increase of physical and cognitive training at home, to complement all other interventions applied by professionals in clinics.
How can people ensure that the information they find online about Parkinson’s is accurate and up to date?
It can be extremely difficult to differentiate between high quality data and misinformation. The easiest and most effective way to filter the good from bad is to always favour information published through associations – for instance, the European Parkinson’s Disease Association (EPDA), Parkinson’s Foundation, or organisations with scientific boards validating their content.
It’s important to be cautious when reading news that presents amazing or almost miraculous treatments. We all hope that in the near future we will have huge therapeutic achievements to share – but they will be presented through publications in scientific journals, scientific societies or congresses, and not posted on the web by people who do not have a solid scientific curriculum.
This difficult period reinforces the need for a close and fruitful collaboration between all. It clarifies the need to be humble when dealing with our health and the uncertainties we still have in many fields of knowledge. These strange and unexpected times will end soon, and we should learn from them.
Need to know
Joaquim Ferreira is a neurologist based in Lisbon, Portugal. He has worked in the field of movement disorders and Parkinson’s for the past 25 years and is a professor of neurology and clinical pharmacology at the University of Lisbon. He is also the founder of Campus Neurológico Sénior (CNS) in Portugal, a neurological disorders centre that focuses on multidisciplinary care for people with Parkinson’s.
For more advice on living well with Parkinson’s, please visit the EPDA website.
The Orchestra Study: investigating a new Parkinson’s disease drug
Would you take part in the UCB research trial?
4 days ago
Study suggests why neurons die in Parkinson’s disease
Researchers at the University of Córdoba, Spain, have discovered how a certain protein may be linked to death of dopamine-producing neurons associated with Parkinson’s. Using animal models of the condition to conduct their study, the team focused on the protein DJ-1 – whose link to Parkinson’s has previously been established, though its exact function was uncertain. The researchers compared neurons in the brains of mice that possessed the gene expressing DJ-1 with those that did not. The findings revealed that dysfunction or absence of the gene expressing the DJ-1 protein could trigger the ‘cell cycle’ (the process by which cells divide), which should not occur under normal conditions. Because neurons lack the capacity to divide, this causes them die – leading to the onset of symptoms linked with Parkinson’s. It is hoped that uncovering these details about the relationship between DJ-1’s absence and Parkinson’s may lead to the development of…
Researchers have finally identified brain cells linked to Parkinson’s disease
For decades, scientists have known that Parkinson’s is associated with the death of dopamine-producing cells in the brain. Now, researchers from the Broad Institute of MIT and Harvard, US, have discovered the specific subtype of brain cells that die in Parkinson’s disease. Using a technique called single-cell RNA signalling, which enables the individual analysis of cells within a tissue for activity and protein production, researchers identified 10 subtypes of dopamine-producing cells within the donated brains of people who died from causes unrelated to Parkinson’s. The team carried out the same investigation on people who had died with Parkinson’s or a condition with similar symptoms called Lewy body dementia. They discovered that only one subtype of the cells had reduced in number – which suggests many of these cells had died while the people were living. It is hoped that the findings could lead to better understanding of Parkinson’s causes and…
Tiny DBS implant shows potential to advance Parkinson’s disease treatment
In an innovative trial by North Bristol NHS Trust, UK, surgeons have succeeded in implanting a tiny deep brain stimulation (DBS) device into a person’s skull. Their aim? To address symptoms of Parkinson’s. Designed with a tiny battery system that is inserted into the skull, the DBS device delivers electric impulses to targeted areas of the brain through electric probes. In doing so, it works to address abnormal brain cell activity associated with Parkinson’s – and may help to ease symptoms. One of around 25 patients selected for the year-long trial has described the device’s impact as “amazing”. Commenting on the results of the trial so far, consultant neurologist Dr Alan Whone of North Bristol NHS Trust said: “We are hopeful that if these findings hold up, we will have a significant technical advance by which to improve Parkinson’s care across the world.”